MegaPro Biomedical Co (ROCO:6827) EV-to-EBIT : -8.98 (As of Jun. 25, 2024)

MegaPro Biomedical Co EV-to-EBIT Chart

MegaPro Biomedical Co Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial					-17.91	-	-9.16	-	-9.95

Competitive Comparison of MegaPro Biomedical Co's EV-to-EBIT

For the Biotechnology subindustry, MegaPro Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MegaPro Biomedical Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MegaPro Biomedical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MegaPro Biomedical Co's EV-to-EBIT falls into.

MegaPro Biomedical Co EV-to-EBIT Calculation

MegaPro Biomedical Co's EV-to-EBIT for today is calculated as:

MegaPro Biomedical Co's current Enterprise Value is NT$1,142.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MegaPro Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-127.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MegaPro Biomedical Co  (ROCO:6827) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

MegaPro Biomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

MegaPro Biomedical Co's Enterprise Value for the quarter that ended in Jun. 2023 was NT$1,754.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MegaPro Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-127.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MegaPro Biomedical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of MegaPro Biomedical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

MegaPro Biomedical Co (ROCO:6827) Business Description